Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy

References

• Christidi E, Brunham LR. Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis. 2021 Apr 1;12(4):339.
   PubMed Web of Science ®Google Scholar
• Mohajeri M, Sahebkar A. Protective effects of curcumin against doxorubicin-induced toxicity and resistance: a review. Crit Rev Oncol Hematol. 2018 Feb;122:30–51.
   PubMed Web of Science ®Google Scholar
• Ma W, Chen Q, Xu W, et al. Self-targeting visualizable hyaluronate nanogel for synchronized intracellular release of doxorubicin and cisplatin in combating multidrug-resistant breast cancer. Nano Res. 2021 Mar 01;14(3):846–857.
   Web of Science ®Google Scholar
• Kanwal U, Irfan Bukhari N, Ovais M, et al. Advances in nano-delivery systems for doxorubicin: an updated insight. J Drug Target. 2018 Apr;26(4):296–310.
   PubMed Web of Science ®Google Scholar
• Tan C, Tasaka H, Yu KP, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333–353.
   PubMed Web of Science ®Google Scholar
• Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. peucetius var. caesius. Biotechnol Bioeng. 1969 Nov;11(6):1101–1110.
   PubMed Web of Science ®Google Scholar
• Niraula NP, Kim SH, Sohng JK, et al. Biotechnological doxorubicin production: pathway and regulation engineering of strains for enhanced production. Appl Microbiol Biotechnol. 2010 Jul;87(4):1187–1194.
   PubMed Web of Science ®Google Scholar
• Gorini S, De Angelis A, Berrino L, et al. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018;2018:7582730.
   PubMed Web of Science ®Google Scholar
• Tuzovic M, Wu PT, Kianmahd S, et al. Natural history of myocardial deformation in children, adolescents, and young adults exposed to anthracyclines: systematic review and meta-analysis. Echocardiography. 2018 Jul;35(7):922–934.
   PubMed Web of Science ®Google Scholar
• Fiallo MM, Tayeb H, Suarato A, et al. Circular dichroism studies on anthracycline antitumor compounds. Relationship between the molecular structure and the spectroscopic data. J Pharm Sci. 1998 Aug;87(8):967–975.
   PubMed Web of Science ®Google Scholar
• Pugazhendhi A, Edison T, Velmurugan BK, et al. Toxicity of Doxorubicin (Dox) to different experimental organ systems. Life Sci. 2018 May 1;200:26–30.
   PubMed Web of Science ®Google Scholar
• Contino M, Guglielmo S, Riganti C, et al. One molecule two goals: a selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells. Eur J Med Chem. 2020 Dec 15;208:112843.
   PubMed Web of Science ®Google Scholar
• Prathumsap N, Shinlapawittayatorn K, Chattipakorn SC, et al. Effects of doxorubicin on the heart: from molecular mechanisms to intervention strategies. Eur J Pharmacol. 2020 Jan 5;866:172818.
   PubMed Web of Science ®Google Scholar
• Smith T, Wolff KA, Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr Top Microbiol Immunol. 2013;374:53–80.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003 Jun 1;97(11):2869–2879.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhou S, and Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano. 2020 Oct 27;14(10):12281–12290. .
   PubMed Web of Science ®Google Scholar
• Amoh Y, Li L, Katsuoka K, et al. Chemotherapy targets the hair-follicle vascular network but not the stem cells. J Invest Dermatol. 2007 Jan;127(1):11–15.
   PubMed Web of Science ®Google Scholar
• Selleri S, Seltmann H, Gariboldi S, et al. Doxorubicin-induced alopecia is associated with sebaceous gland degeneration. J Invest Dermatol. 2006 Apr;126(4):711–720.
   PubMed Web of Science ®Google Scholar
• Osataphan N, Phrommintikul A, and Chattipakorn SC, et al. Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: insights for future interventions. J Cell Mol Med. 2020 Jun;24(12):6534–6557.
   PubMed Web of Science ®Google Scholar
• Nguyen TT, Lim JS, Tang RM, et al. Fitness profiling links topoisomerase II regulation of centromeric integrity to doxorubicin resistance in fission yeast. Sci Rep. 2015 Feb 11;5:8400.
   PubMed Web of Science ®Google Scholar
• Borišev I, Mrđanovic J, Petrovic D, et al. **Nanoformulations of doxorubicin: how far have we come and where do we go from here? Nanotechnology. 2018 Aug 17;29(33):332002. .
   PubMed Web of Science ®Google Scholar
• Buzun K, Bielawska A, and Bielawski K, et al. DNA topoisomerases as molecular targets for anticancer drugs. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1781–1799. .
   PubMed Web of Science ®Google Scholar
• Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene. 1999 Aug 19;18(33):4681–4688.
   PubMed Web of Science ®Google Scholar
• Coldwell K, Cutts SM, Ognibene TJ, et al. Detection of Adriamycin-DNA adducts by accelerator mass spectrometry. Methods Mol Biol. 2010;613:103–118.
   PubMedGoogle Scholar
• Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908.
   PubMed Web of Science ®Google Scholar
• Hajipour Verdom B, Abdolmaleki P, Behmanesh M. The static magnetic field remotely boosts the efficiency of doxorubicin through modulating ROS behaviors. Sci Rep. 2018 Jan 17;8(1):990.
   PubMedGoogle Scholar
• Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol. 1998 Aug;25(4 Suppl 10):10–14.
   PubMed Web of Science ®Google Scholar
• Wang S, Kotamraju S, Konorev E, et al. Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: the role of hydrogen peroxide. Biochem J. 2002 Nov 1;367(Pt 3):729–740.
   PubMed Web of Science ®Google Scholar
• Wang S, Song P, Zou MH. Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1. J Biol Chem. 2012 Mar 9;287(11):8001–8012.
   PubMed Web of Science ®Google Scholar
• de Luca A, Moroni N, Serafino A, et al. Treatment of doxorubicin-resistant MCF7/Dx cells with nitric oxide causes histone glutathionylation and reversal of drug resistance. Biochem J. 2011 Dec 1;440(2):175–183.
   PubMedGoogle Scholar
• Gonçalves M, Mignani S, and Rodrigues J, et al. A glance over doxorubicin based-nanotherapeutics: from proof-of-concept studies to solutions in the market. J Control Release. 2020 Jan 10;317:347–374.
   PubMed Web of Science ®Google Scholar
• Jiang L, Gao Z-M, Ye L, et al. A tumor-targeting nano doxorubicin delivery system built from amphiphilic polyrotaxane-based block copolymers. Polymer. 2013 Aug 23;54(19):5188–5198.
   Web of Science ®Google Scholar
• Chen F, Chen H, Duan X, et al. Molecularly imprinted polymers synthesized using reduction-cleavable hyperbranched polymers for doxorubicin hydrochloride with enhanced loading properties and controlled release. J Mater Sci. 2016 Oct 01;51(20):9367–9383.
   Web of Science ®Google Scholar
• Rusetskaya NV, Lukyanova NY, Chekhun VF. Molecular profile and cell cycle in MCF-7 and MCF-7/Dox cells exposed to conventional and liposomal forms of doxorubicin. Exp Oncol. 2009 Sep;31(3):140–143.
   PubMedGoogle Scholar
• Ma P, Mumper RJ. Anthracycline nano-delivery systems to overcome multiple drug resistance: a comprehensive review. Nano Today. 2013 Jun 1;8(3):313–331.
   PubMed Web of Science ®Google Scholar
• Yu P, Yu H, Guo C, et al. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles. Acta Biomater. 2015 Mar;14:115–124.
   PubMed Web of Science ®Google Scholar
• Dai X, Yue Z, Eccleston ME, et al. Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells. Nanomed. 2008 Mar;4(1):49–56.
   PubMed Web of Science ®Google Scholar
• Hovorka O, St’astný M, Etrych T, et al. Differences in the intracellular fate of free and polymer-bound doxorubicin. J Control Release. 2002 Apr 23;80(1–3):101–117.
   PubMed Web of Science ®Google Scholar
• Minko T, Kopecková P, Kopecek J. Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release. 2001 Apr 28;71(3):227–237.
   PubMed Web of Science ®Google Scholar
• Malugin A, Kopecková P, Kopecek J. Liberation of doxorubicin from HPMA copolymer conjugate is essential for the induction of cell cycle arrest and nuclear fragmentation in ovarian carcinoma cells. J Control Release. 2007 Dec 4;124(1–2):6–10.
   PubMed Web of Science ®Google Scholar
• Yousefpour P, Atyabi F, Vasheghani-Farahani E, et al. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine. 2011;6:1977–1990.
   PubMed Web of Science ®Google Scholar
• Min Y, Caster JM, Eblan MJ, et al. Clinical Translation of Nanomedicine. Chem Rev. 2015 Oct 14;115(19):11147–11190.
   PubMed Web of Science ®Google Scholar
• Caster JM, Patel AN, Zhang T, et al. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jan;9(1).
   PubMed Web of Science ®Google Scholar
• Havel H, Finch G, Strode P, et al. Nanomedicines: from bench to bedside and beyond. AAPS J. 2016 Nov;18(6):1373–1378.
   PubMed Web of Science ®Google Scholar
• Hassan S, Prakash G, Ozturk A, et al. Evolution and clinical translation of drug delivery nanomaterials. Nano Today. 2017 Aug;15:91–106.
   PubMed Web of Science ®Google Scholar
• Lancaster JM Micro-RNA profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy. Google Patents. 2012.
   Google Scholar
• Salamone SJ, Courtney JB, He S Doxorubicin immunoassay. Google Patents. 2011.
   Google Scholar
• Filippini S, Lomovskaya N, Fonstein L, et al. Process for preparing doxorubicin. Google Patents. 2001.
   Google Scholar
• Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998 Feb;16(2):683–691.
   PubMed Web of Science ®Google Scholar
• Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004 Oct;95(1):1–8.
   PubMed Web of Science ®Google Scholar
• Lyon PC, Griffiths LF, Lee J, et al. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound. 2017;5:28.
   PubMedGoogle Scholar
• Celsion. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) i n Treatment of Hepatocellular Carcinoma (HCC). 2014. [cited 2019 July 17] Available from: https://clinicaltrials.gov/ct2/show/NCT00617981
   Google Scholar
• Celsion. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). [cited 2019 June 17]. Available from: https://Clinicaltrials.Gov/Ct2/Show/Study/NCT021126562014
   Google Scholar
• Gaspani S, Milani B. Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx. GaBi J. 2013;2(2):60–62.
   Google Scholar
• Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer. 2006;106(4):848–858.
   PubMed Web of Science ®Google Scholar
• Miller K, Cortes J, Hurvitz SA, et al. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 2016;16(1):1–11.
   Google Scholar
• MM-302 Misses Endpoint in Phase II Hermione Trial [Internet]. 2016. Available from: https://adcreview.com/news/mm-302-misses-endpoint-phase-ii-hermione-trial/
   Google Scholar
• Lopez-Pousa A, Bui Nguyen B, Garcia del Muro X, et al. A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: a GEIS trial. J clin oncol. 2011;29(15_suppl):10072.
   Web of Science ®Google Scholar
• Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012;13(12):1234–1241.
   PubMed Web of Science ®Google Scholar
• Kerklaan BM, Jager A, Aftimos P, et al. NT-23 phase 1/2a study of glutathione pegylated liposomal doxorubicin (2B3-101) in breast cancer patients with brain metastases (BCBM) or recurrent high grade gliomas (HGG). Neuro Oncol. 2014;16(suppl_5):v163–v163.
   Google Scholar
• Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009;34(6):1629–1636.
   PubMed Web of Science ®Google Scholar
• Onxeo to host a Conference Call today to comment on the main findings from ReLive Phase III Study of Livatag® [Internet]. 2017. [cited July 17]. Available from: https://www.onxeo.com/onxeo-host-conference-call-today-comment-main-findings-relive-phase-iii-study-livatag/
   Google Scholar
• Valle J, Lawrance J, Brewer J, et al. A phase II, window study of SP1049C as first-line therapy in inoperable metastatic adenocarcinoma of the oesophagus. J clin oncol. 2004;22(14_suppl):4195.
   Web of Science ®Google Scholar
• Matsumura Y, Hamaguchi T, Ura T, et al. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer. 2004;91(10):1775–1781.
   PubMed Web of Science ®Google Scholar
• Whittle JR, Lickliter JD, Gan HK, et al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015;22(12):1889–1894.
   PubMed Web of Science ®Google Scholar
• Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997 Mar;15(3):987–993.
   PubMed Web of Science ®Google Scholar
• Symon Z, Peyser A, Tzemach D, et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999 Jul 1;86(1):72–78.
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007 Sep 1;25(25):3892–3901.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419–436.
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012 Jun 10;160(2):117–134.
   PubMed Web of Science ®Google Scholar
• Krown SE, Northfelt DW, Osoba D, et al. Use of liposomal anthracyclines in Kaposi’s sarcoma. Semin Oncol. 2004 Dec;31(6 Suppl 13):36–52.
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440–449.
   PubMed Web of Science ®Google Scholar
• Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol. 2011 Aug;7(8):937–945.
   PubMed Web of Science ®Google Scholar
• Chen J, He CQ, Lin AH, et al. Thermosensitive liposomes with higher phase transition temperature for targeted drug delivery to tumor. Int J Pharm. 2014 Nov 20;475(1–2):408–415.
   PubMedGoogle Scholar
• Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother. 2009 Feb;10(2):333–343.
   PubMed Web of Science ®Google Scholar
• Batist G, Barton J, Chaikin P, et al. Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy. Expert Opin Pharmacother. 2002 Dec;3(12):1739–1751.
   PubMedGoogle Scholar
• Leonard RC, Williams S, Tulpule A, et al. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009 Aug;18(4):218–224.
   PubMed Web of Science ®Google Scholar
• Chan S, Davidson N, Juozaityte E, et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004 Oct;15(10):1527–1534.
   PubMed Web of Science ®Google Scholar
• Safra T. Cardiac safety of liposomal anthracyclines. Oncologist. 2003;8(Suppl 2):17–24.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Appeldoorn CC, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PloS One. 2014;9(1):e82331.
   PubMed Web of Science ®Google Scholar
• Gaillard PJ, Visser CC, Appeldoorn CCM, et al. Enhanced brain drug delivery: safely crossing the blood–brain barrier. Drug Discovery Today. 2012 Jun 01;9(2):e155–e160.
   Google Scholar
• Dalesio O. Clinical and pharmacological study with 2B3-101 in patients with breast cancer and leptomeningeal metastases. Clinicaltrials.Gov., editor. [cited July 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT018187132013.
   Google Scholar
• Kattan J, Droz JP, Couvreur P, et al. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs. 1992 Aug;10(3):191–199.
   PubMed Web of Science ®Google Scholar
• Onxeo. Orphan oncology products: produits orphelins en oncologie. [cited July 17]. Available from: http://www.onxeo.com/en/nos-produits/orphelins-oncologie/#tabs-1-32019
   Google Scholar
• Onxeo. Livatag® (Doxorubicin TransdrugTM) follow up demonstrates significant survival increase in advanced hepatocellular carcinoma patients. [cited July 17]. Available from: http://www.onxeo.com/wpcontent/2011
   Google Scholar
• Onxeo. Onxeo announces top-line results from relive phase iii study of livatag® in advanced hepatocellular carcinoma. [cited July 17]. Available from: https://www.onxeo.com/onxeo-announces-top-line-results-relive-phase-iii-study-livatag-advanced-hepatocellular-carcinoma/2017.
   Google Scholar
• Reynolds JG, Olivier KJ, Hendriks BS, et al. Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents. Google Patents. 2016.
   Google Scholar
• Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res off J Am Assoc Cancer Res. 2002 Apr;8(4):1172–1181.
   PubMed Web of Science ®Google Scholar
• Park JW, Kirpotin DB, Hong K, et al. Tumor targeting using anti-her2 immunoliposomes. J Control Release. 2001 Jul 6;74(1–3):95–113.
   PubMed Web of Science ®Google Scholar
• Schütz CA, Juillerat-Jeanneret L, Mueller H, et al. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine (Lond). 2013 Mar;8(3):449–467.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002 Mar 15;20(6):1668–1676.
   PubMed Web of Science ®Google Scholar
• Hopewel JW, Duncan R, Wilding D, et al. Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent. Hum Exp Toxicol. 2001 Sep;20(9):461–470.
   PubMed Web of Science ®Google Scholar
• Sohail M, Guo W, Li Z, et al. Nanocarrier-based drug delivery system for cancer therapeutics: a review of the last decade. Curr Med Chem. 2021:28(19):3735-3772
   PubMed Web of Science ®Google Scholar
• Ofner III CM, Cammarata C, Rhodes B, et al. High molecular weight biodegradable gelatin-doxorubicin conjugate. Google Patents. 2019.
   Google Scholar
• Zhao Y, Cai Z, Tang X, et al. Preoperative denosumab may increase the risk of local recurrence of giant-cell tumor of bone treated with curettage: a systematic review and meta-analysis. J Cancer. 2021;12(2):508.
   PubMed Web of Science ®Google Scholar
• Egorov M, Goujon J-Y, Le Bot R, et al. Hydrosoluble hydroxybisphosphonic derivatives of doxorubicin. Google Patents. 2019.
   Google Scholar
• Nieciecka D, Celej J, Żuk M, et al. Hybrid system for local drug delivery and magnetic hyperthermia based on SPIONs loaded with doxorubicin and epirubicin. Pharmaceutics. 2021;13(4):480.
   PubMed Web of Science ®Google Scholar
• Qiao X, van der Zanden SY, Wander DP, et al. Uncoupling DNA damage from chromatin damage to detoxify doxorubicin. Proc Nat Acad Sci. 2020;117(26):15182–15192.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu Y Legumain activated doxorubicin derivative as well as preparation method and application thereof. Google Patents. 2018.
   Google Scholar
• Borbély J, Csikós Z, Koncz G, et al. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it. Google Patents. 2015.
   Google Scholar
• Floyd RA, Kopke RD, Choi C-H, et al. Nitrones as therapeutics. Free Radic Biol Med. 2008;45(10):1361–1374.
   PubMed Web of Science ®Google Scholar
• Oliveira C, Benfeito S, Fernandes C, et al. NO and HNO donors, nitrones, and nitroxides: past, present, and future. Med Res Rev. 2018;38(4):1159–1187.
   PubMed Web of Science ®Google Scholar
• Garland WA, Frenzel BD Doxorubicin adjuvants to reduce toxicity and methods for using the same. Google Patents. 2015.
   Google Scholar
• Garland WA, Frenzel BD Doxorubicin adjuvants to reduce toxicity and methods for using the same. Google Patents. 2012.
   Google Scholar
• Demeule M, Che C, Gabathuler R, et al. Etoposide and doxorubicin conjugates for drug delivery. Google Patents. 2014.
   Google Scholar
• Demeule M, Che C, Gabathuler R, et al. Etoposide and doxorubicin conjugates for drug delivery. Google Patents. 2016.
   Google Scholar
• Fiume L, Di Stefano G, Lanza M Process for the preparation of doxorubicin conjugates with lactosaminated human albumin. Google Patents. 2009.
   Google Scholar
• Ruangwattanasuk O Doxorubicin derivatives and uses thereof. Google Patents. 2020.
   Google Scholar
• Tomas Etrych K, Petr CPKU, Prague TM, Holesov, Blanka Rihova, Prague. Grafted macromolecular conugates of doxorubcn with anticanceractivity and method of ther preparation. Google Patents. 2013.
   Google Scholar
• Xi J, Li M, Jing B, et al. Long-circulating amphiphilic doxorubicin for tumor mitochondria-specific targeting. ACS Appl Mater Interfaces. 2018 Dec 19;10(50):43482–43492.
   PubMed Web of Science ®Google Scholar
• Jose J, Kumar R, Harilal S, et al. Magnetic nanoparticles for hyperthermia in cancer treatment: an emerging tool. Environ Sci Pollut Res. 2020;27(16):19214–19225.
   PubMed Web of Science ®Google Scholar
• Raucher D, Bidwell III G, Priebe W, et al. Thermally-targeted delivery of medicaments including doxorubicin. Google Patents. 2012.
   Google Scholar
• Tian B, Liu S, Wu S, et al. pH-responsive poly (acrylic acid)-gated mesoporous silica and its application in oral colon targeted drug delivery for doxorubicin. Colloids Surf B Biointerfaces. 2017;154:287–296.
   PubMed Web of Science ®Google Scholar
• Klinski E, Patel K, Pietrzynski G, et al. Doxorubicin formulations for anti-cancer use. Google Patents. 2012.
   Google Scholar
• Johdo O, Nakao T, Yoshioka T Crystallization of doxorubicin hydrochloride. Google Patents. 2003.
   Google Scholar
• Tasca E, Del Giudice A, Galantini L, et al. A fluorescence study of the loading and time stability of doxorubicin in sodium cholate/PEO-PPO-PEO triblock copolymer mixed micelles. J Colloid Interface Sci. 2019;540:593–601.
   PubMed Web of Science ®Google Scholar
• Rashida A, Karmali B Method of reducing cardiaclevels of doxorubcn when given as orotate salt. Google Patents. 2012.
   Google Scholar
• Martins JMA, Rabelo-Santos SH, do Amaral Westin MC, et al. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, TIMP-1, TIMP-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis. BMC Cancer. 2020;20(1):1–11.
   Web of Science ®Google Scholar
• Kratz F Protein-binding doxorubicin peptide derivatives. Google Patents. 2010.
   Google Scholar
• Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022.
   PubMedGoogle Scholar
• Bissery M-C. Method of treating cancer with docetaxel and doxorubicin. Google Patents. 2011.
   Google Scholar
• Rozencweig M, Goldfarb RH, Forenza S Non-pegylated liposomal doxorubicin triple combination therapy. Google Patents. 2011.
   Google Scholar
• Gabizon A, Ohana P, Shmeeda H Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C. Google Patents. 2020.
   Google Scholar
• Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): products on the market. Int J Nanomedicine. 2014;9:4357–4373.
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev. 2017 Jan 1;108:25–38.
   PubMed Web of Science ®Google Scholar